Entry id

1_9lsmvys9

Modern day adjuvant clinical trials often give us the endpoint as well of distant relapse-free survival, which, of course, is critically important to us and our patients because distant recurrence metastasis in a vital organ – bone, liver, lungs, for example – unfortunately almost always lead eventually to death. And that is what we most want to avoid in women who are diagnosed with breast cancer. So, improvement in distant relapse-free survival means fewer metastases and fewer deaths from breast cancer, critically important to us in practice.